Microsoft word - importance of research on rare diseases.doc
Importance of Research on Rare
Diseases and Orphan Drugs
There are significant moral, scientific, economic and policy imperatives for conducting research into
A rare disease as defined in the EU Orphan Medicinal Products Regulation (2000) is a disease with
an instance of less than five in 10,000 of the population (1).
POINT 1: The Impact of Rare Disease Research on Population Health
Patients affected by rare diseases are at a disadvantage because the cost of developing new
treatments is not offset by the financial rewards from sales under normal market conditions.
Therefore there are significant unmet medical needs resulting in increased morbidity and mortality
for these patients and a tremendous burden on the individual, the community and on the state (2).
The specific features associated with rare diseases (low individual patient numbers, diversity,
geographical location) require that research is developed and financed at a national and European
level in order to optimise funding, infrastructures and technological platforms (3).
When considered individually by disease, the number of patients afflicted by a rare disease appears
low. However, there are over 7,000 rare diseases and it is estimated that up to 3.5% of the
population will be affected. For Ireland that represents a cumulative total population of
approximately 140,000 patients (4).
Research has shown that many major diseases can be subdivided into individual diseases, some of
which are classified as rare. This is often the case with cancer and heart disease.
Society supports innovation in healthcare to benefit patients, including rare disease patients.
Innovation must continue to be reimbursed and of course show value, which must be measurable
and demonstrable. However showing value requires sufficient time to gather data. By limiting
funding for rare disease research in Ireland we are bucking not only a national but European and
Global impetus in this area (5).
POINT 2: Scientific/Clinical Value
Personalised Medicine, Advanced Therapies and
Fundamental and Innovative Clinical Research on Rare Diseases
Currently research into common diseases has a greater chance of finding breakthroughs once sub-
classified into individual diseases. Often these are classified as rare e.g. inherited prostate cancer,
insulin dependent diabetes etc. This is because there can be considerable variation from patient to
patient with respect to effective response to current
medicines (illustrated in figure 1).
Almost 50% of cancers are Rare Diseases, when
appropriately classified (6). Genetic subdivision of
patient populations further enhances the possibility
of targeting drugs based not just on clinical and
pathological diagnosis, but on genetic diagnosis.
This has potential to save vast sums of money by
administering drugs only to those who will benefit.
The groundbreaking discoveries made for
extremely uncommon malignancies such as
chronic myelogenous leukaemia (CML), seminoma,
gastrointestinal stromal tumour (GIST) are
examples of this (7). Research focused on an
Diagram of ineffective rate of medicines for
abnormal gene and its protein product allows for
the rational design of a drug to treat conditions. Research into Gleevec has spawned a whole field of research into drugs such as Tyrosine Kinase Inhibitors (8). More recently genetics has uncovered that in treating
hypertension, it may be possible to sub classify patients into
those who metabolise the drug Warfarin faster than others,
helping to tailor doses for patients rather than present trial and
The value of fundamental research is amplified when linked to
clinical outcomes in a translational research environment. Basic
and translational research can be carried out in parallel to
Carmustine Implants -
clinical trials in order to add the value of utilising patient samples
and records by additional local research into more fundamental
aspects of the disease. This is highlighted in the molecular sub
categorisation of patients recruited and ultimately looking for
correlations with treatment outcomes. These clinical trials take
advantage of translational research networks and clinical trials
Sample of drugs which
centres to turn basic research findings into clinical therapies.
have been re-purposed for new conditions due to Orphan Drugs
This can result in significant potential for intellectual property
and economic benefit for the research organisation, the clinical
The potential for re-evaluating existing drugs for conditions like Rare Diseases is significant; Figure
2 lists examples of this. These would not have been financially viable without the advantages
offered under the orphan drugs legislation.
The re-purposing of a drug cannot happen in a vacuum without fundamental research on the natural
history and biology of many rare diseases or on the cause of the disease to identify suitable drug
targets. The key word in this area is translational and the useful knowledge results in a dynamic
bidirectional scaling of the value chain of research, from the laboratory to the bedside and back.
POINT 3: The Economic Impact of Rare Disease Research
A blossoming of the US biotech industry
followed the passing of the orphan drugs
legislation in 1983. This resulted in the
establishment of more than 50% of the
world’s leading biotech companies including
Amgen (Forbes listed worlds largest biotech
company, 2008 revenue $15 billion;
products Epogen, for anaemia, and
Neupogen- immune modulator) Genzyme
(Cerezyme for Gaucher disease,
Fabryzyme for Fabry disease, $4.6 billion)
and Genentech (10). In the US from 1983 to
2004, 256 orphan drugs received market
authorisation. This was directly attributed to
the stimulation of the Orphan Drugs Act
Fig 3: Impact of Orphan drugs regulation in EU on
The implementation of the European Orphan
Drug legislation in 2000 resulted in a dramatic (30%) increase in new Biotech companies. A
significant number of start-ups have been created with many existing companies beginning
research on rare diseases. According to the same study, jobs related to orphan medicinal products
increased at a quicker pace than general industry trends. All companies surveyed increased their
total number of employees in the European Community between 2000 and 2004 (an average
increase of 43%). R&D expenditure on rare diseases grew faster than general medicinal R&D
investment. The companies surveyed increased R&D investment in orphan medicinal products more
than two-fold on average between 2000 and 2004 (12).
POINT 4: Global and European Policy in Rare Disease Research
The European Union Economic and Social Committee has recommended making national
strategies on rare diseases an integral part of national public health policy. This recommendation
was adopted by the European Council of Ministers on June 9, 2009. Member states are being
urged to identify ongoing research and research resources in order to establish state of the art
facilities and to assess the research landscape in the area of rare diseases (13).
Rare Disease as a public health priority was a primary focus of the French presidency of the
European Commission (July ’08 - Jan ’09). This remains so for the current Czech presidency and
the incoming Swedish presidency (July ’09 - Jan ’10) (14). All of these developments are further
supported by the establishment of The Office of Director for Rare Diseases at the European
In late May 2009 the US NIH announced the launch of a $24 million Therapeutics for Rare and
Neglected Diseases Programme (TRND). This is the first integrated drug development pipeline
within the NIH designed to produce new treatments for rare and neglected diseases. It is specifically
intended to stimulate research collaborations with academic scientists working on rare illnesses
European and global trends in human health and research policy support national policies on rare
diseases which in turn call for the sustainability and development of research in this area. As a
country with a small population we will require international support in our efforts and will need to
show our support and understanding of the area by investing in research and contributing to the
Dr. Patrick Corley – Assistant Director of Research, Fighting Blindness
Ms. Avril Daly – Chair, Genetics & Rare Disorders Organisation (GRDO)
Genzyme corporation – Personal medicines and sustainability (Presentation)
Council of the European Union - Draft Recommendation on a European action in the field of rare diseases. 9010/09 page 24 section 3, recommendation 2
IPPOSI/IMB meeting “Medicines for Rare Diseases – an Opportunity for Patients, Science and Industry”, Dublin, 9 November 2007 – citing Orpha.net figures
Genzyme Value of Innovation – Value of Innovation Presentation
Calculated from prevalence rates of cancers from National Cancer Registry of Ireland
Eck MJ, “The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.” Curr Opin Cell Biol. 2009 Apr;21(2):288-95. Epub 2009 Feb 11.
Müller BA. “Imatinib and its successors--how modern chemistry has changed drug development. “Curr Pharm Des. 2009;15(2):120-33
Takeuchi F, et. al.”A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009 Mar; 5(3):e1000433. Epub 2009 Mar 20.
Sales and revenue figures from individual company annual reports.
Reaves ND. “A model of effective health policy: the 1983 Orphan Drug Act.” J Health Soc Policy. 2003;17(4):61-71.
Commission Working Staff document Brussels 20.6.2006 SEC (2006) 832 on the experience acquired as a result of the application of Regulation (EC) No 141/2000 on orphan medicinal products and account of the public health benefits obtained
Council Recommendation in the field of Rare diseases 9.06.09 2947TH Employment Society Policy Health & Consumer Affairs.
EURODIS - website rare diseases on the French agenda of French Presidency of EU
US NIH Office of Rare Diseases (ORDR) website
Fachinformation (Zusammenfassung der Merkmale des Arzneimittels/SPC)bis zu 500 mg Naproxen] bis zu 750 mg Naproxen]12 Jahren und ErwachsenenWirkstoff: Naproxen1 Tablette enthält 250 mg Naproxen. Sonstiger Bestandteil: Lactose-Monohydrat. Die vollständige Auflistung der sonstigenDolormin GS darf bei Kindern unter 12 Jah-Bei älteren Patienten kommt es unter NSAR-ren nicht angewendet werde
Exam Preparation Guidelines Arthrogram: Barium Swallow, Modified Barium Swallow: Barium enema (BE), Air Contrast Barium Enema (ACBE): Nothing to eat or drink after midnightFleet prep kit 18-hour protocolNothing to eat or drink 3 hours prior to examNo solid food on day of examNothing to eat or drink 3 hours prior to examNo solid food on day of exam1/2 Dulcolax suppository 3 hours pr